EUVIMEDEUVIMED entdecken
Open Access

Functional and Patient-Reported Outcomes in the Atorvastatin versus Placebo Trial of Hemorrhagic Cerebral Cavernous Malformations: An Exploratory Study

Georgeio Sader, Roberto J Alcazar-Felix, Aditya Jhaveri, Bader Ali, Agnieszka Stadnik, Justine Lee, Robert Shenkar, Kevin Treine, Nichol McBee, Romuald Girard, Richard E Thompson, Daniel F Hanley und 2 weitere

Cerebrovascular Diseases · 24.04.2026 · 1-9

DOI: 10.1159/000552209 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cerebrovascular Diseases, online erschienen am 24.04.2026. Verfasst von Georgeio Sader und 13 weiteren Autor:innen. Beteiligte Einrichtung: Section of Neurovascular Surgery, Department of Neurological Surgery, University of Chicago Medicine and Biological Sciences, Chicago, Illinois, USA. Die Arbeit nennt 14 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NINDS NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Limited longitudinal data exist regarding functional and patient-reported outcome (PRO) in symptomatic hemorrhage (SH) from cerebral cavernous malformation enrolled in clinical trials.

Methods

We assessed functional outcome using the modified Rankin Scale (mRS) and NIH Stroke Scale (NIHSS), and PRO using European Quality of Life 5-Dimension and Visual Analog Scale (EQ-5D-3L and VAS) and PRO-measurement information system (PROMIS-29) at baseline, 1 year, and 2 years in patients randomized to atorvastatin and placebo in the prospective, double-blinded Atorvastatin Treatment of Cavernous Angioma Symptomatic Hemorrhage Exploratory Proof of Concept (AT CASH EPOC) trial. Sensitivity analyses compared score change in cases with and without prospective SH and in those with or without a ≥6% increase in lesional iron content on quantitative susceptibility mapping (QSM), consistent with occult bleeding.

Results

Of 64 patients with paired QSM and outcome data, baseline characteristics were similar; baseline mRS distributions differed between groups but were similar at years 1 and 2. No significant differences in functional and PRO appeared between the atorvastatin and placebo groups. While there was a decline in PROMIS-29 sleep disturbance (57.1% SH vs. 7.7% no SH; p < 0.01), fatigue (57.1% SH vs. 21.2% no SH; p = 0.06), and social role (44.4% SH vs. 16% no SH; p = 0.07) domains with prospective SH over 2 years, the small numbers of patients limit the generalizability. These functional and PRO declines were generally specific but poorly sensitive for identifying SH or occult bleeding.

Discussion

Despite more frequently reported side effects with atorvastatin in the trial, there were no significant differences in functional or PRO in the atorvastatin and placebo groups. Functional and PRO decline were highly specific but poorly sensitive for identifying prospective SH or occult bleeding.

Schlagwörter

Stichwörter der Autor:innen

AtorvastatinCerebral cavernous malformationFunctional outcomeSymptomatic hemorrhage

Autor:innen und Institutionen

  • Section of Neurovascular Surgery, Department of Neurological Surgery, University of Chicago Medicine and Biological Sciences, Chicago, Illinois, USA.
  • BIOS Clinical Trial Coordinating Center and the Trial Innovation Center, Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
  • Department of Neurology, Mayo Clinic, Rochester, Minnesota, USA, flemming.kelly@mayo.edu.

Förderung

  • NINDS NIH HHS

Zitieren

APA

Sader, G., Alcazar-Felix, R. J., Jhaveri, A., Ali, B., Stadnik, A., Lee, J., Shenkar, R., Treine, K., McBee, N., Girard, R., Thompson, R. E., Hanley, D. F., Awad, I., & Flemming, K. D. (2026). Functional and Patient-Reported Outcomes in the Atorvastatin versus Placebo Trial of Hemorrhagic Cerebral Cavernous Malformations: An Exploratory Study. Cerebrovascular Diseases, 1-9. https://doi.org/10.1159/000552209

Vancouver

Sader G, Alcazar-Felix RJ, Jhaveri A, Ali B, Stadnik A, Lee J, et al. Functional and Patient-Reported Outcomes in the Atorvastatin versus Placebo Trial of Hemorrhagic Cerebral Cavernous Malformations: An Exploratory Study. Cerebrovascular Diseases. 2026:1-9. doi:10.1159/000552209

BibTeX
@article{Sader2026,
  author = {Sader, Georgeio and Alcazar-Felix, Roberto J and Jhaveri, Aditya and Ali, Bader and Stadnik, Agnieszka and Lee, Justine and Shenkar, Robert and Treine, Kevin and McBee, Nichol and Girard, Romuald and Thompson, Richard E and Hanley, Daniel F and Awad, Issam and Flemming, Kelly D},
  title = {Functional and Patient-Reported Outcomes in the Atorvastatin versus Placebo Trial of Hemorrhagic Cerebral Cavernous Malformations: An Exploratory Study},
  journal = {Cerebrovascular Diseases},
  year = {2026},
  pages = {1--9},
  doi = {10.1159/000552209}
}
Kostenlos starten →